Osteogenic Differentiation of Human Umbilical Cord Peri-vascular Cells using Low Intensity Pulsed Ultrasound

Taghreed A Aldosary1, Hasan Uludag2, Michael Doschak3 and Tarek El-Bialy4*
1National Guard Health Affairs, Community and Preventive Medicine, Jeddah, Saudi Arabia
2Department of Chemical and Material Engineering, University of Alberta, Edmonton, Canada
3Pharmacy and Pharmaceutical Sciences, Dentistry/Pharmacy Centre, University of Alberta, Edmonton, Canada
4Medicine and Dentistry, Department of Dentistry, Dentistry/Pharmacy Centre, University of Alberta, Edmonton, Canada

Abstract

The objective of this experiment was to explore the possible effect of low intensity pulsed ultrasound (LIPUS) on the osteogenic differentiation of harvested passage-4 Human umbilical cord peri-vascular cells (HUCPV-Cs). HUCPV-Cs were divided into two groups: a treatment group that received LIPUS for 10 minutes for days 1, 7, and 14 and a control group that received a sham treatment utilizing osteogenic media. The results demonstrated nonsignificant differences in cell count, ALP, DNA content, and CD90. Statistically significant expression of OPN and PCNA was observed on day 14 in the LIPUS treated group. Nucleostemin expression in the LIPUS-treated group was nonsignificant on days 1 and 7. However, a selective increase in the osteogenic markers was observed in the LIPUS treated group on day 7 for ALP and OCN and on day 14 for OPN. Future experiments are required to explore the possible effects of different application times and/or techniques of LIPUS on the behaviour of HUCPV-Cs.

Keywords: Low Intensity Pulse Ultrasound; Stem cells; Human Umbilical Cord Perivascular Cells; Osteogenic differentiation

Introduction

Mesenchymal stem cells represent a promising future for medicine [1,2]. They introduce a new tool for clinical concepts that support cellular therapy [1,2]. Obtaining MSCs from bone marrow is an invasive procedure [1,3]. Frequency, differentiation potential, and life span of bone marrow-MSCs decrease with age [4-6]. Therefore, many researches have been investigating an alternative source for mesenchymal stem cells in order to find a cure for many ailments [6]. It has been shown that cryopreserved umbilical cord blood from unrelated donors is a safe source of transplantable hematopoietic stem cells for clinical transplantation [6]. They reported that those cells have high rate of engraftment and low rate of grade III-IV acute graft versus host disease (GVHD) and even in recipients of human leukocyte antigens (HLA) unrelated grafts are remarkable [6]. Umbilical cord cells have been progressively used as an alternative source for hematopoietic stem cells (HSC) for allogenic stem cell transplants [3-8]. It has been reported that MSCs from bone marrow, umbilical cord blood and adipose tissue can achieve a success in stem cell therapy [9]. Their clinical application may be based on their capacity of differentiation, but much more on their frequency, and expansion potential [9]. However, the lack of common standards for initial cell preparation remains an obstacle for standardization of research methodology and the clinical application of umbilical cord-MSCs [10,11].

"Mesenchymal stem cells derived from the umbilical cord vein are functionally similar to bone marrow MSCs" [12]. Isolation of umbilical cord MSCs (UCMSCs) is less invasive than bone marrow derivations, and because of the fetal origin of UCMSCs, their proliferative and differentiation potential provide an excellent resource [12]. In a comparative study, it has been documented that human umbilical cord perivascular cells (HUCPV-Cs) have higher capacity of differentiation and proliferation than bone marrow MSCs [13]. In addition, HUCPV-Cs were shown to have a faster rate of osteogenic differentiation compared to bone marrow MSCs [13]. Umbilical cord provides a pool of cells of vast abundance, and with the advantage of less donor site morbidity [14]. Gang et al. reported that umbilical cord blood derived cells (UCB-DCs) express high potential to differentiate into variety of mesenchymal linages cells [15]. He also claimed that UCB-DCs is an excellent substitute source for human-MSCs [15]. Human umbilical cord stromal cells express almost the same characteristics of mesenchymal stem cells [16,17]. It has been reported that the umbilical cord stromal cells shows high capability to differentiate into osteogenic, adipogenic, cardiomyogenic, and chondrogenic cell types [16]. A new technique for harvesting, culturing, and osteogenic differentiation of HUCPV-Cs has been reported [18]. Ultimately, the blood that remains inside the human umbilical cord is usually considered a valid source of hematopoietic stem cells [19,20]. Furthermore, Kim et al. reported that umbilical cord blood is an excellent source of profound mesenchymal progenitor cells (MPCs) characterized by the capacity for self-renewal and differentiation into multiple lineages which make them comparable to the same cells (MPCs) from different origin [21]. Goodwin et al. proven that umbilical cord blood cells are a potential source of cells for multiple organ cellular therapeutics [22].

Many reports have demonstrated that LIPUS enhances bone remodeling and bone formation as well as it decreases healing time [23-32]. Mechanical stresses have been reported to enhance activities of osteoclasts and osteoblasts leading to increase bone remodeling and bone regeneration, respectively [33]. Different forms of mechanical stress such as LIPUS have been clinically tested for their ability to enhance new bone formation [34].

Acceleration of fracture healing by LIPUS was attributed to the pressure waves that trigger a complex series of biochemical and
molecular events at the cellular level [35]. An increase in alkaline phosphatase (ALP) activity was detected in human osteoblast cultures after continuous exposure to the low intensity pressure waves of LIPUS [36].

This study investigated whether LIPUS has a stimulatory effect on osteogenic differentiated HUCPV-Cs that can potentially increase the differentiation capacity of these cells during certain periods of time (10 minutes/day for 1, 7 and 14 days). The influence of LIPUS was assessed using different methods including cell count, ALP assay, DNA assay, real-time PCR, and immunophenotyping of cells derived from HUCPV-Cs by flow-cytometry analysis.

Materials and Methods

This study has been approved by the Health Research Ethics Board at the University of Alberta, Edmonton, Canada (approval number 6431, 2006).

Cell culture

HUCPV-Cs were donated by Professor Joh E Davis at the University of Toronto at P0. HUCPV-Cs were obtained from patients undergoing full-term caesarean sections after obtaining standard patient’s consent and isolation of the cells were completed according to methods described by Sarugaser et al. [18].

HUCPV-Cs at passage 0 were thawed and seeded in T-75 cm² tissue culture flasks (Sigma Aldrich). The cell cultured in osteogenic media included Dulbecco’s modified Eagle’s medium with low glucose (DMEM-LG) (GIBCO, Invitrogen) supplemented with 1% antibiotic-antimycotic (Sigma Aldrich), 15% fetal bovine serum (FBS), 5 mM β-glycerophosphate (Sigma Aldrich), 50 μg/ml L-ascorbic acid (Sigma Aldrich) [18], and 10⁻⁴ M dexamethasone (Sigma Aldrich). The cells were incubated at 37°C in 5% CO₂ and the initial cell density used was 3.6 × 10⁶/ml. Ten days were implemented for the expansion of HUCPV-Cs by flow-cytometry analysis.

Immunophenotyping using flow-cytometry analysis

HUCPV-Cs at passage 0 were thawed and seeded in T-75 cm² tissue culture flasks (Sigma Aldrich). The cell cultured in osteogenic media included Dulbecco’s modified Eagle’s medium with low glucose (DMEM-LG) (GIBCO, Invitrogen) supplemented with 1% antibiotic-antimycotic (Sigma Aldrich), 15% fetal bovine serum (FBS), 5 mM β-glycerophosphate (Sigma Aldrich), 50 μg/ml L-ascorbic acid (Sigma Aldrich) [18], and 10⁻⁴ M dexamethasone (Sigma Aldrich). The cells were incubated at 37°C in 5% CO₂ and the initial cell density used was 3.6 × 10⁶/ml. Ten days were implemented for the expansion of HUCPV-Cs until P3 and the media were changed every 2–3 days. The cells at P3 were harvested and trypsinized when their confluence reached 80% (4.2 × 10⁸/ml) using 0.25% trypsin (GIBCO, Invitrogen). The cells at P4 were collected in 50 ml tubes, centrifuged, then plated into nine 6 well plates (Sigma Aldrich) at 2 × 10⁴/ml. Four sets of “LIPUS” devices were obtained from SmileSonic Inc., Edmonton, Canada with 4 transducers placed below the wells and coupled to the well bases with standard ultrasound coupling gel transducers that was previously calibrated. A total of 27 wells were treated by these LIPUS devices for 10 min/day for 14 days where the ultrasound frequency, intensity, and duration were identical to that has been used for bone fracture repair experimentally and clinically [23–32]. Sham devices were used to treat the other 27 wells (control group) using the same transducers without turning on the machines. HUCPV-Cs were assessed for their differentiation capacity at day 1, 7 and 14 consecutively. The ultrasound transducers generate 1.5-Mhz ultrasound waves of 200-µs bursts at an intensity of 200 µm bursts at an intensity of 30 mW/cm² and pulse repetition frequency of 1 KHz. To maintain the consistency of electrical waveforms, the transducers were calibrated before and after applications using TDS1012C-EDU digital oscilloscope (Tektronix, Canada and an ultrasound power-meter (model UPM-DT-1AV from Ohmic Instruments, Easton, MD, USA). The incubator temperature was maintained at 37°C during the application of LIPUS.

Cell proliferation and DNA quantification assay

Measurement of DNA amount was performed using 1 ml of the lysed cell solution with the CyQUANT Cell proliferation kit (Molecular Probe, Invitrogen, Burlington, ON, Canada). Measurement of DNA quantity was performed by the CyQUANT cell proliferation kit assay (Molecular Probe, Invitrogen, Burlington, ON, Canada). Cell proliferation was determined by comparing cell’s DNA content for treated samples with untreated controls. The CyQUANT kit protocol requires binding of the cell with the dye solution, incubation for 30–60 minutes, and then measurement of fluorescence was performed in a microplate reader (Fluoroskan Ascent, Thermo Labsystems, Finland). The assay was designed to generate a linear analytical response in a 96 well microwell (Molecular Probe, Invitrogen, Burlington, ON, Canada). The DNA standard provided with the CyQUANT kit was used to determine the DNA concentrations in each cell group. Quanification of DNA used a fluorescence plate reader (excitation at 480 nm; emission at 527 nm) in accordance with the manufacturer’s instructions.

Immunophenotyping using flow-cytometry analysis

Cell surface antigen phenotyping assay was used for characterization of the HUCPVCs at passage 4 on days 1, 7 and 14 after pulsed with LIPUS and compared with control (sham) group. The following cell-surface epitopes were labeled with anti-human antibodies: CD31 (PECAM-1) fluorescein isothiocyanate (FITC, BD Biosciences, Mississauga, ON, Canada), CD34-R-phycocerythrin (R-PE, BD Biosciences, Mississauga, ON, Canada), CD45-phycocerythrin (PE, BD Biosciences, Mississauga, ON, Canada), CD90 (Thy1) R-phycocerythrin (R-PE, BD Biosciences, Mississauga, ON, Canada), MHC I (HLA-A,B,C) R-phycocerythrin (R-PE, BD Biosciences, Mississauga, ON, Canada), MHC II (HLA-DR) fluorescein isothiocyanate (FITC, BD Biosciences, Mississauga, ON, Canada). Cell surface antigen phenotyping assay was used for characterization of the HUCPVCs at passage 4 on days 1, 7 and 14 after pulsed with LIPUS and compared with control (sham) group. The following cell-surface epitopes were labeled with anti-human antibodies: CD31 (PECAM-1) fluorescein isothiocyanate (FITC, BD Biosciences, Mississauga, ON, Canada), CD34-R-phycocerythrin (R-PE, BD Biosciences, Mississauga, ON, Canada), CD45-phycocerythrin (PE, BD Biosciences, Mississauga, ON, Canada), CD90 (Thy1) R-phycocerythrin (R-PE, BD Biosciences, Mississauga, ON, Canada), MHC I (HLA-A,B,C) R-phycocerythrin (R-PE, BD Biosciences, Mississauga, ON, Canada), MHC II (HLA-DR) fluorescein isothiocyanate (FITC, BD Biosciences, Mississauga, ON, Canada). Details about these markers are

Cell count

HUCPV-Cs were washed using PBS (GIBCO, Invitrogen, Burlington, ON, Canada) then trypsinized. Cells and medium were collected in 15 ml tubes and were spun for 6 minutes at 600 rpm (Treated group separated from Control group). The supernatant was vacuumed away. Cells were counted using Beckman Coulter Machine (Beckman coulter Canada Inc., Burlington, ON, Canada).
described in Table 1. The HUCPVCs were suspended and prepared using standard direct staining protocols [40,41].

**Quantitative real-time-PCR analysis (Q-PCR)**

Total RNA was extracted from each triplicate group of both LIPUS treated and sham (control) groups using the RNaseasy Mini Kit (Qiagen, Mississauga, ON, Canada). Fluorometric quantification of RNA samples was performed at 260 nm using SybrGreen (Molecular Probes, OR, USA), according to the manufacturer’s recommendation. One µg of the total RNA was used to synthesize single stranded DNA using the Omniscript Reverse Transcription kit (Qiagen, Mississauga, ON, Canada). The primers for real-time PCR were designed with Primer Express 2.0 software from Applied Biosystems (AB, Foster City, CA, USA.). TaqMan®Gene Expression Assays were used to perform RT-PCR reactions (Applied Biosystems AB, Foster City, CA, USA.). The TaqMan®MGB probes and primers were mixed to a target concentration of 18 µM for each primer and 5 µM for the probe and the amplifications were carried out in a final reaction volume of 10 µl. Gene’s assays ID and gene’s symbols are explained in Table 2 the reaction mixtures were aliquoted into 96-well ABI reaction plate. The plates were then placed in an ABI Prism 7500 fast system V 1.4.0 Applied Bio-system q-PCR machine under the following conditions: stage 1 consisted of 95°C for 10 min; stage 2 consisted of 40 cycles of 95°C for 15 s, followed by 60°C for 1 min. The q-PCR data were analyzed with SDS 7500 Fast system V.2.01 software (AB, Foster City, CA, USA.).

**Statistical analysis**

Multi variate analysis of variance MANOVA was used to compare the expansion capacities of treated (LIPUS) group and control (sham) group using SPSS software package (version 16.0; SPSS Inc., Chicago, IL, USA.). Analysis of the flow cytometry data and qPCR data were completed using two-way ANOVA and the differences were statistically considered significant at (p < 0.05).

**Results**

The HUCPVCs were assessed on days 1, 7 and 14 after application of LIPUS as well as control group. The cell count in the LIPUS treated group was decreased on days 1 and 14, however, an increase noted on day 7 but not statistically significant.

There was no difference in cell proliferation assay as reflected by DNA content equalized with ALP in the LIPUS treated group (p < 0.9).

<table>
<thead>
<tr>
<th>Markers</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD90</td>
<td>Mesenchymal stromal cell marker</td>
</tr>
<tr>
<td>CD31</td>
<td>Endothelial cell marker</td>
</tr>
<tr>
<td>CD34</td>
<td>Hematopoietic cells and vascular endothelium marker</td>
</tr>
<tr>
<td>CD45</td>
<td>Differentiated hematopoietic cell marker</td>
</tr>
<tr>
<td>MHC I</td>
<td>Recognized during graft rejection and found on all nucleated cells</td>
</tr>
<tr>
<td>MHCII</td>
<td>A marker for B-lymphocytes, macrophages and dendritic cells</td>
</tr>
</tbody>
</table>

**Table 1:** Description of cell surface markers.

<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Gene Symbol</th>
<th>Assay ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endogenous Control Human GAPDH (Glyceraldehyde 3-phosphate dehydrogenase)</td>
<td>GAPDH</td>
<td>4333764F</td>
</tr>
<tr>
<td>Osteocalcin (OCN)</td>
<td>BGLAP</td>
<td>Hs00609452_g1</td>
</tr>
<tr>
<td>Osteopontin (OPN)</td>
<td>SPP1</td>
<td>Hs00959009_m1</td>
</tr>
<tr>
<td>Proliferating cell nuclear antigen (PCNA)</td>
<td>PCNA</td>
<td>Hs99999177_g1</td>
</tr>
<tr>
<td>Nucleostemin (NST)</td>
<td>GNL3</td>
<td>Hs00205071_m1</td>
</tr>
</tbody>
</table>

**Table 2:** Genes used for qPCR analysis.

During osteogenic differentiation, no significant difference in DNA content could be detected between samples treated with LIPUS for 10 minutes per day and the untreated control group. DNA content was 0.5 fold higher on day 7 in the LIPUS treated group (0.018 ± 0.003), whereas it was lower on day 14 in the LIPUS treated group (0.015 ± 0.006) compared with the control group.

HUCPVCs expressed a non-significant increase of ALP activity in the LIPUS treated group compared to the control group (p < 0.9). ALP activity was slightly reduced on day 1 (0.018 ± 0.006), higher on day 7 (0.018 ± 0.003), and slightly lower on day 14 (0.015 ± 0.006) in the LIPUS treated group compared to the control group (Figure 1).

Immunophenotyping (FACS) was performed to analyze cell surface markers on HUCPVCs at passage 4. Cells were gated according to size and expressed surface markers. HUCPVCs were negative for CD31 (found on endothelial cells, platelets, macrophages) and MHCII [HLA-DR]. MHCII antigens are cell surface markers involved in graft-versus-host disease and the rejection of tissue transplants in HLA mismatched donors. HUCPVCs were also negative for CD34 (a hematopoietic stem cell marker) and CD45 (leukocyte common antigen). On other hand, HUCPVCs were strongly positive for CD90 (a mesenchymal progenitor–specific marker) and moderately positive for MHC1I [HLA-A, B, C] (recognized during graft rejection, found in all nucleated cells). HUCPVCs in the LIPUS treated group expressed a high level of CD90 on day 14 compared with control (Figure 2 and Table 3).

We further investigated our original hypothesis, that LIPUS-expanded HUCPVCs will maintain their osteogenic differentiation potential, by assessing the expression of nucleostemin, PCNA, OCN, and OPN after equalization to the endogenous control gene GAPDH. Nucleostemin is a marker of undifferentiated human mesenchymal stromal stem cells and is involved in regulation of MSC proliferation [42]. HUCPVCs expressed lower levels of nucleostemin in the LIPUS treated group on days 1 and 7 compared to the control, with a nonsignificant higher expression on day 14 (Table 4). On the other hand, the level of PCNA was significantly higher in the LIPUS treated group on day 14 (p < 0.001).

The levels of OCN expression were approximately 0.2 fold lower in the LIPUS treated group on day 1, 1.5 fold higher on day 7, and 0.5 fold higher on day 14. These responses were, however, statistically nonsignificant. The level of OPN was 1 fold higher on day 14 (p < 0.001), whereas it was 0.2 fold lower on day 1 and almost comparable to the control group on day 7. These findings suggest that LIPUS treatment for 10 min/day may enhance osteogenic differentiation of HUCPVCs on day 14 and beyond (Figure 3 and Table 4).

**Discussion**

MSCs have shown to be differentiated into osteoblastic lineage [16,18]. Osteogenic differentiation of MSCs was established in culture media containing ascorbic acid, β-glycerophosphate, and dexamethasone. It has been demonstrated previously that HUCPVCs are capable to be differentiated into osteogenic lineage in vitro after incubation in osteogenic media for 5, 21, and 28 days [16,18]. The stimulatory effect of LIPUS has been documented in many studies using a variety of cell lineages such as osteoblasts, chondrocytes, and marrow-derived stromal cells [43-46].

Our results showed a non-significant increase in HUCPVCs osteogenic differentiation capacity after 1 day of LIPUS application. On day 7 of LIPUS application, there have been increases in some
osteogenic markers, namely OCN and ALP, and there was a significant increase in OPN on day 14. No significant differences in cell count, DNA content, or immunophenotypic characteristics were detected between the LIPUS treated preparation and a sham treated control.

DNA content, ALP activity, and calcium content were used as alternate measures for cellular activities in some experimental studies. The expression of these has been shown to decrease by mechanical stress, such as stretching and loading [47]. Similarly, it has been shown that intermittent loading of mechanical stress reduces the activation of mechanosensitive cation channels on osteoblast-like cells [48]. Intermittent cyclic loading has been used as a form of applied mechanical stress [47,48]. Some of these findings were consistent with our results; that is, the down-regulation of some cellular markers after exposure to LIPUS [47-50].

Non-significant increases of CD90 and nucleostemin on day 14 were noted in the LIPUS treated group. In addition, non-significant changes in levels of OCN were observed: OCN was approximately 0.2 fold lower on day 1, 1.5 fold higher on day 7, and 0.5 fold higher on day 14. Statistically significant higher expression of PCNA and OPN in the LIPUS treated group compared to the control was observed on day 14. These findings suggest that the stimulatory effect of LIPUS application to upregulate OPN gene expression in HUCPV-Cs occurs after 14 days of daily. Lee et al. reported that LIPUS enhances cell viability by increasing expression of cell viability related genes such as PCNA [51-53]. Biomechanical stimulation and LIPUS were effective tools in improving repair of damaged cells and enhance the synthesis of matrix protein [53]. It has been reported that application of LIPUS for 20 days to human mandibular fracture haematoma-derived cells (MHCs) significantly increase osteogenic gene expression and osteogenic protein [54]. Also, it has been reported that LIPUS enhances bone repair in animals, upregulate osteogenic genes expression, and significantly increase alkaline phosphatase and bone morphogenic protein after 25 days of application [55]. Furthermore, it has been shown that LIPUS stimulation has profoundly enhanced the multifunctional effect that is relevant to alveolar bone regeneration which plays an important factor in periodontal healing [56]. They reported that human alveolar bone-derived mesenchymal stem cells (hABMSCs) treated with 50 mW/cm² show a significant increase in osteogenic genes expression, alkaline phosphatase, and calcium deposit compared to untreated group after 10
minutes/day application for 3 weeks [56]. In summary, future studies may aim to investigate the possible stimulatory effect of increasing LIPUS application time to 20 minutes/day for 20 days or more for the possibility that more significant osteogenic gene expression might occur.

**Conclusion**

This study explored the effect of daily application of LIPUS for 10 minutes/day for 1, 7 and 14 days on the osteogenic differentiation of HUCPV-Cs. The results of this study are as follow: HUCPV-Cs treated with LIPUS demonstrate increase in CD90 level at day 14 compared to untreated group. Moreover, LIPUS application to HUCPV-Cs stimulated showed statistically significant increase in PCNA, and OPN gene expression on day 14, respectively. These results suggest that LIPUS has stimulatory effect on osteogenic differentiation of HUCPV-Cs especially after 14 days of application. More studies may be conducted to investigate the possible effect of different LIPUS frequencies, power or treatment time on the osteogenic differentiation of HUCPV-Cs.

**References**


